by 10% each month. The main endpoint was a steroid dependence defined by the recurrence of PMR symptoms and/or the increase of CRP at two times during the decrease of prednisone. Results: We included 14 patients younger than 60 years old (average age 54+/-0.8 years) and 28 patients older than 65 years old (average age 75.8 +/-1.5 years). The population younger than 60 years was mainly male (60% VS 27%, p<0.05). Both groups were similar in terms of morning stiffness (2,1±0,4 VS 1,9±0,3 hours; p>0.05), disease duration (4,2±0,8 VS 4,1±0,6 months; p>0.05), leukocytes rate (8,3±1,37 VS 8±0,7 G/L; p>0.05) and percentage of antinuclear antibodies rate over 1/320 (20% VS 10%; p>0.05). However, regarding to local inflammation, the intensity of FDG uptake highlighted by the Pet scan was lower among young patients (score of 16,9±1,7 VS 26,5±3,0; p<0.05). Furthermore, we observed a significant difference concerning therapeutic response according to the age: 60% of the young patients developed a steroid dependence compared to20% in group of old patients (p<0.05). Moreover, the introduction of methotrexate was necessary for 35% of the young patients against 6.5% (p<0.05). Conclusions: Our study is the first to highlight the age as a bad prognosis factor in case of PMR. This difference is independent to the systemic inflammation and surprisingly, local inflammation (assessed by the TEP score) is more important in elderly people. Young patients suffering from PMR are mostly men and are more dependent on steroids. Thus, methotrexate could be straightaway proposed, particularly in patient younger than 60 years old. 
by 10% each month. The main endpoint was a steroid dependence defined by the recurrence of PMR symptoms and/or the increase of CRP at two times during the decrease of prednisone. Results: We included 14 patients younger than 60 years old (average age 54+/-0.8 years) and 28 patients older than 65 years old (average age 75.8 +/-1.5 years). The population younger than 60 years was mainly male (60% VS 27%, p<0.05). Both groups were similar in terms of morning stiffness (2,1±0,4 VS 1,9±0,3 hours; p>0.05), disease duration (4,2±0,8 VS 4,1±0,6 months; p>0.05), leukocytes rate (8,3±1,37 VS 8±0,7 G/L; p>0.05) and percentage of antinuclear antibodies rate over 1/320 (20% VS 10%; p>0.05). However, regarding to local inflammation, the intensity of FDG uptake highlighted by the Pet scan was lower among young patients (score of 16, 9±1, 7 VS 26, 5±3, 0; p<0.05) . Furthermore, we observed a significant difference concerning therapeutic response according to the age: 60% of the young patients developed a steroid dependence compared to20% in group of old patients (p<0.05). Moreover, the introduction of methotrexate was necessary for 35% of the young patients against 6.5% (p<0.05). Conclusions: Our study is the first to highlight the age as a bad prognosis factor in case of PMR. This difference is independent to the systemic inflammation and surprisingly, local inflammation (assessed by the TEP score) is more important in elderly people. Young patients suffering from PMR are mostly men and are more dependent on steroids. Thus, methotrexate could be straightaway proposed, particularly in patient younger than 60 years old. Background: Adult-onset Still's disease (AOSD) is an acute and systemic inflammatory disorder that is characterized by high spiking fever, evanescent rash, arthralgia/arthritis and hyperferritinemia. However, recent reports showed that not only typical evanescent salmon-colored rash but also atypical skin lesions, persistent pruritic papules and plaques, could be associated with AOSD. Objectives: The aim of this study is to assess the clinical significance of dyskeratotic cells in skin lesions of Japanese patients with AOSD. Methods: We retrospectively assessed clinical and histological findings of skin lesions including persistent pruritic skin lesions in Japanese patients with AOSD (n=12). Moreover, we compared serological and histological finding of AOSD with that of dermatomyositis (DM) (n=6), drug eruptions (DE) (n=6), and Graft versus Host disease (GVHD) (n=6). Results: AOSD with persistent pruritic skin lesions (n=7) histologically showed dyskeratotic cells only in upper layer of epidermis and horny layer without intraepidermal infiltrations of inflammatory cells. These dyskeratotic cells were positive by TUNEL and single stranded DNA (ssDNA) stainings, suggesting apoptotic cells. AOSD with evanescent rash (n=5) histologically showed no dyskeratosis. On the other side, the pathological findings of DM (n=6), DE (n=6) and GVHD (n=6) had dyskeratotic cells in all layers of epidermis with inflammatory cells infiltrations. Notably, AOSD with dyskeratosis (n=7) had significant higher levels of serum IL-18 (74,300∼307,000 pg/ml) than AOSD without dyskeratosis (n=5). Conclusions: AOSD with persistent pruritic skin lesions is characterized and specific by prominent epidermal apoptosis, especially involving the upper layers. Therefore, it could play a pivotal role to recognize the atypical skin lesions of AOSD for correct early diagnosis. Finally, the high levels of serum IL-18 might be related with epidermal apoptosis of keratinocyte in AOSD. Background: Adult onset Still Disease (AOSD) is a systemic inflammatory disease presenting various non-specific symptoms like fever, arthralgia and pharyngalgia. Those symptoms are mimicking common cold, which could lead to the delayed diagnosis. However, little is known about the profiles and development of symptoms in very early phase before diagnosis. Objectives: To clarify the clinical course of AOSD symptom development in very early phase and its effect on the diagnosis delay. Methods: Consecutive patients with AOSD with enough information in our hospital were enrolled. Initial symptoms before and at diagnosis were investigated in detail. The gradual course from the initial symptoms to the fulfilment of Yamaguchi criteria for AOSD was examined. Results: A total of 51 patients were enrolled. The mean age at diagnosis was 45.0±18.9 years old and 41 (80%) were female. All patients were met with the Yamaguchi criteria. The mean duration from the first symptom to diagnosis was 50.4 days. The duration from the first symptom to the first visit to the medical facility including a general physician was 19.1 days, and that from the first medical facility visit to the first blood test was 8.0 days. While the first symptom was arthralgia in 29 (34.1%), fever in 20 (23.5%), and eruption in 20 (23.5%), pharyngalgia in 13 (15.3%), at diagnosis, fever was found in all patients, eruption in 47 (92.2%), arthralgia in 45 (88.2%), pharyngalgia in 34 (66.7%), lymphadenopathy and/or splenomegaly in 35 (68.6%), increased white blood cell (WBC) count in 44 (86.3%), ferritin elevation in 42 (82.4%), liver enzyme elevation in 41 (80.4%), negative rheumatoid factor (RF) and anti-nucleolar antibody (ANA) in 30 (58.8%). Arthralgia developed 41.9 days prior to the diagnosis, fever 40.9 days, eruption 29.5 days, pharyngalgia 24.5 days and lymphadenopathy and/or splenomegaly 14.8 days. WBC increase was detected 17.8 days prior to the diagnosis, negative RF and ANA 15.1 days, liver enzyme elevation 14.6 days, and ferritin elevation 10.9 days. At 14 days from the first symptom, 32 (62.7%) met 3 of Yamaguchi criteria, 23 (45.1%) met 4, and 19 (37.3%) met 5. At 28 days, 40 (78.4%) met 3 of Yamaguchi criteria, 32 (62.7%) met 4, and 27 (52.9%) met 5. The duration to diagnosis was significantly shorter in the patients with eruption developing within 7 days since the first symptoms than those without (35.2 vs 74.3 days, p=0.03) Conclusions: The mean duration from the first symptom to the diagnosis of AOSD was approximately 50 days, and only a half of the patients met Yamaguchi criteria at 28 days after first symptom. The CAPS guideline panel consisted of 19 international members, including patient representation. The panel used the GradePro software to brainstorm and prioritize potential questions and outcomes. Systematic reviews were performed for each question. To supplement the published evidence, we compiled raw data for mortality from the CAPS Registry, and systematically elicited expert opinion from the panel members using a systematic observation form. For each question an evidence profile and evidence to decision table was generated and shared.
Results:
The question prioritization step generated 47 questions, which were ranked to identify the top priorities. The top 10 questions were chosen for guideline development, yielding 7 therapy and 3 diagnostic questions. The outcome generation step yielded 7 outcomes. The questions were addressed during an in-person panel meeting, held on April 27, 2016 in Barcelona, Spain, with follow-up via webinar on June 3, 2016, and with web-based voting completed July 31, 2016.
Recommendations were developed for all questions and will be discussed in detail.
Conclusions: Ten recommendations were issued by the CAPS Guideline Panel to assist clinicians in diagnosis and management of suspected CAPS patients. Future research is needed to improve evidence quality in rare diseases such as CAPS. The GIN-McMaster Guideline Development Checklist and the GRADE methodology were effective in producing a rigorous guideline in this rare disease. [4] . However, blockade of these checkpoints results in a multitude of autoimmune sequelae including joint disease. As these therapies become first-line in oncology, they will likely place a significant burden on rheumatology services. Objectives: To establish the prevalence of rheumatological manifestations of checkpoint blockade in a non-trial standard care setting. Methods: All patients treated with Nivolumab or Ipilimumab (as single agent or in combination) in a standard care setting within a single centre were included and the number of suspected cases with rheumatological manifestations identified from the case records. Results: 75 patients have been treated with Nivolumab single agent and 12 with combination Nivolumab plus Ipilimumab in Oxford over the last 15 months. Within that cohort, there were 7 suspected cases of joint disease giving a potential prevalence of 8%. Of those 7, 2 had confirmed disease requiring therapy, both had received Nivolumab/Ipilimumab combination. Both cases were rheumatoid factor and CCP negative. One case responded to prednisolone only, while the second case was refractory to steroids, methotrexate and infliximab but responded to IL-6 blockade with Tocilizumab.
Conclusions:
We observed an approximate 8% prevalence of checkpoint mediated autoimmune joint disease within a relatively short follow up period of 15 months. The longer-term prevalence may be higher. Both patients requiring therapy had been exposed to Ipilimumab suggesting the inflammatory joint toxicity with this agent may be higher than that caused by Nivolumab. Checkpoint immunotherapy is set to become the first-line standard of care in a number of cancers. This will lead to an increased demand for rheumatology services. The rheumatology community needs to develop strategies and trials in order to classify and treat these patients appropriately. 
